A new era in the treatment of cystic fibrosis!

Vertex has introduced Alyftrek, a new drug that is already approved in the US for children aged 6 and over.

The main advantage is the expanded spectrum of mutations, which includes not only those that are amenable to treatment with Trikafta, but also for some mutations of the 3rd, 4th and 5th classes.

Key differences from Cafrio:

– Covers a wider range of mutations.

– Only taken once a day.

But the main news is a breakthrough in the treatment of all patients with cystic fibrosis! Clinical trials of the mRNA drug VX-522 are already underway.

This innovative therapy is designed for people with any mutation who previously could not benefit from existing treatments. The first results of the studies are expected to be available as early as 2025.

We expect Alyftrek to be approved in Europe, the UK, Australia, Canada and Switzerland next year